Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 11/20 | 0.40 |
| ▸ | JAK1 | P23458 | 11/20 | 0.40 |
| ▸ | JAK2 | O60674 | 10/20 | 0.40 |
| ▸ | TYK2 | P29597 | 2/20 | 0.40 |
| ▸ | CNR2 | P34972 | 3/20 | 0.34 |
| ▸ | SYK | P43405 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | RORC | P51449 | 1/20 | 0.31 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.30 |
| ▸ | CCR1 | P32246 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2378169 | 0.91 | JAK3 (0.38) | JAK3JAK1JAK2TYK2CNR2 | |
| SCHEMBL2378332 | 0.88 | JAK3 (0.41) | JAK3JAK1JAK2TYK2CNR2 | |
| SCHEMBL2378268 | 0.88 | JAK1 (0.40) | JAK3JAK1JAK2TYK2CNR2 | |
| SCHEMBL2485227 | 0.86 | JAK3 (0.43) | JAK3JAK1JAK2TYK2CNR2 | |
| SCHEMBL14751953 | 0.84 | JAK2 (0.53) | JAK3JAK1JAK2TYK2SYK | |
| SCHEMBL2378414 | 0.84 | JAK3 (0.39) | JAK3JAK1JAK2TYK2CNR2 | |
| SCHEMBL2377922 | 0.81 | JAK1 (0.39) | JAK3JAK1JAK2TYK2 | |
| SCHEMBL2379097 | 0.80 | JAK2 (0.45) | JAK3JAK1JAK2TYK2CNR2 | |
| SCHEMBL2379093 | 0.80 | JAK2 (0.45) | JAK3JAK1JAK2TYK2CNR2 | |
| SCHEMBL2376836 | 0.79 | JAK1 (0.64) | JAK3JAK1JAK2TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011117145-A2 | PYRROLOPYRAZINE KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-09-29 | — | — | WO | disclosed |
| US-20110230462-A1 | Pyrrolopyrazine Kinase Inhibitors | HENDRICKS ROBERT THAN | 2011-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230462-A1 | Pyrrolopyrazine Kinase Inhibitors | SYK, ZAP70, BTK | JAK3 13/4885JAK1 6/4885JAK2 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.